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Abstract
Background: This study was conducted to find out whether boys with constitutional 
delay in growth and puberty (CDGP) could attain their target height and predicted adult 
height (PAH) in adulthood or not.
Methods: After measuring the height, weight, pubertal stage, parental height and 
bone age data of the patients at their first presentation were extracted from the files 
and their height and weight were measured at the end of the study, wrist X-Ray was 
performed in order to determine the bone age. PAH was calculated using  
Bayley–Pinneau method and target height was estimated by mid parental height. Final 
or near final heights of the patients were measured and compared with the target 
height and PAH.
Results: The mean age at presentation and the end of study was 15.2 ± 0.95, 
20 ± 0.75 years respectively. Mean of bone age at the beginning of study was 
12.97 ± 1 years and at the end of study were 17.6 ± 0.58 years. Mean of delayed bone 
age was 2.2 ± 0.82 years. Mean of the primary measured heights was 150.16 ± 7 cm 
(138–160 cm). Mean of final or near final heights was 165.7 ± 2.89 cm (161–170.5 cm). 
Final or near final heights in our subjects were smaller than either their PAH (165.7 ± 2.89 
vs 170.7 ± 5.17) (P value <0.005) or target height (165.7 ± 2.89 vs 171.8 ± 4.65) (P value 
<0.0001).
Conclusion: Most patients with CDGP do not reach their target height or predicted adult 
height; they are usually shorter than their parents and general population. Such patients 
need to be followed up until they reach their final height and, in some cases, adjunctive 
medical treatment might be indicated.
Introduction
Constitutional delay in growth and puberty (CDGP) is 
the most common cause of short stature and puberty 
delay in boys (1, 2, 3, 4). This condition is considered 
as a normal variation, and affected individuals typically 
have a slow pattern of growth during childhood and 
adolescence. The patients are identified with short stature, 
delay bone age and puberty. Their bone age lags behind 
their chronological age, which is providing an indication 
of remaining the growth potential. According to some 
literature (5) and Butenandt (6) in most cases is expected 
to eventually grow their genetic potential height after 
puberty and attain normal adult height.
However, recent studies performed by Soliman et al. 
(7) and Poyrazoğlu et al. (8) indicate the final height (FH) 
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of these children are short related to parental height. They 
should be treated before puberty to reach to the target 
height (TH) and predicted adult height (PAH).
Soliman et  al. (7) believed in children with CDGP 
height deficit at onset of puberty, shorter time between 
onset of puberty and pubertal growth spurt and attenuated 
peak growth velocity are correlated with final height. 
Therefore, many of them do not attain their target height 
or their predicted adult height.
CDGP may contribute to psychological difficulties, 
which can be improved with treatment. Based on the 
guidelines adopted by the U.S Food Administration, boys 
who have prediction final height of less than 160 cm, are 
candidates for treatment with growth hormone. Therefore, 
this study was conducted to find out whether boys with 
CDGP could attain their TH and PAH in adulthood or not.
Material and methods
Subjects and study design
The study was approved by Iran University of Medical 
Sciences, and consent has been obtained from each 
patient or subject after full explanation of the purpose and 
nature of all procedures used. The study was conducted in 
accordance with the guidelines on good clinical practice 
and with ethical standards for human experimentation 
established by the Declaration of Helsinki.
Study design and study population
In this cohort study, fifteen boys with CDGP who 
presented to Research Center of Endocrinology and 
Metabolism Tehran, Iran in a 7-year period were included. 
The average height of the patients at the beginning of the 
study was ≤−2 SDS, and their puberty had not started until 
the average age of 13.84  years; all patients had normal 
physical examination and their hormone profiles (growth 
and thyroid hormone) were normal. They did not have 
any skeletal abnormalities or systemic disease.
Measurements
The height, weight, pubertal stage, parental height and 
bone age data of the patients at their first presentation 
were extracted from the files and their height and 
weight were measured at the end of the study (bone age 
>17 years) and the patients’ puberty stage was determined 
based on Tanner Staging (9). Simultaneous bone age was 
determined by wrist radiography based on Greulich and 
Pyle’s radiographic atlas (10). PAH was calculated by 
Bayley–Pinneau method (11). The Bayley–Pinneau method 
uses a series of tables that provide the child’s predicted 
percentage of adult height. TH in boys is calculated by 
parental heights using following formula: (12).
Target Height
Mother s Height Father s Height
cm=
+
+
’ ’
2
6 5.
Final height (height of boys after closure of the 
growth plates) skeletal abnormalities or near final height 
(bone age >16 years) of patients were compared with these 
tow predicted adult heights and target height, statistical 
correlations of PAH and TH with final or near final height 
were evaluated (Fig. 1).
Statistical analysis
Data were analyzed using SPSS, version 16.0 software (SPSS). 
All data are expressed as mean ± s.d. Kolmogorov–Smirnov 
test was performed to evaluate normal distribution of 
quantitative variables. Paired T test was used to compare 
the differences between the values of continuous variables 
at the end of the study. Linear regression analysis used to 
investigate the relationship (predictors) of near final and 
parental heights as independent variables. All two-sided 
P value less than 0.05 were regarded as being statistically 
significant.
Results
A total of 15 boys with CDGP were recruited in the 
current sboldtudy. The mean ages at presentation and at 
the end of the study were 15.2 ± 0.95 and 20 ± 0.75 years 
respectively. Baseline characteristics of the patients with 
CDGP are given in Table 1. Near final or final height and 
Figure 1
Comparison of final height (FH) with target height (TH) and predicted 
adult height (PAH).
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bone age at the end of the follow-up (17.6 ± 0.58  year), 
predicted adult height and mid-parental height are shown 
in Table  2. As it is shown, final or near final height in 
subjects was smaller than their predicted adult height 
(165.7 ± 2.89 vs 170.7 ± 5.17) and target height (165.7 ± 2.89 
vs 171.8 ± 4.65). Paired T-test analysis demonstrated 
that this difference was statistically significant (P value 
<0.0001). There was no significant correlation between 
SDS of final or near final height and patient’s baseline 
BMI (P > 0.05, R Spearman = 0.145). There was significant 
difference between SDS of height at the beginning of the 
study and SDS of final or near final height (P < 0.0002, 
T = −4.7). Correlations between final or near final height 
and all other parameters are shown in Table 3.
Discussion
Constitutional delay of growth and puberty is the 
most common cause of short stature in boys, entailing 
significant psychosocial implications. Our study showed 
that there is a significant difference between FH, TH and 
PAH. In addition, boys with CDGP would not reach their 
PAH or even their TH based on their genetic potential, 
and they would continue to be shorter than their peers of 
the same age, even after their puberty.
In parallel, Poyrazogluand et  al. (8) investigated the 
clinical characteristics of 105 boys and 46 girls with CDGP 
in a retrospective study. Forty-one patients reached the 
final height. The average final height of these patients 
was less than their TH or their PAH. In another study 
by Wehkalampi et  al. (13) investigated the growth of 
70 adult men with a history of CDGP among 21 had 
received testosterone and 31 had progressive height SD 
reduction between 3 and 9  years of age, but 39 lacked 
such a reduction. Final height of these patients was 
compared to their TH, and they concluded that those 
with early height SD reduction would not reach their FH 
in proportion to their potential genetic height, but those 
lacking this reduction would reach their TH. Moreover, 
Sperlich et  al. (14) studied the growth of 49 boys with 
CDGP at two different age cross sections with average 
calendar age of 13.3 years and 22.9 years. In the first stage, 
the average bone age of the subjects was 11.1 years, and 
the average height was less than the 5th percentile for 
their calendar age. Average patients FH was 171.3 cm that 
was significantly less than their average TH of 173 cm. In 
addition, FH about 32.6% of the patients were more than 
5 cm shorter than their PAH (By Bayley–Pinneau method).
On the other hand, in another study by Crown et al. 
(15), the growth of 43 boys with CDGP was followed, 
since their average calendar age of 14 years up to their FH. 
These patients' FH were −1.6 SDS. There was no significant 
difference between their FH and PAH, but a significant 
difference existed between FH and TH in these patients. 
Furthermore, some other studies revealed the different 
results in patients with CDGP reaching their TH and PAH. 
Salerno et al. (16) have evaluated final height in 20 patients 
with CDGP (11 boys and 9 girls); boys’ average height in 
their pre-pubertal stage was −2.65 DS that improved to 
−1.3 in their adulthood. The average boys’ final height was 
166.4 cm, which was close to the TH (165.7 cm) and PAH 
(167.3 cm), respectively. Finally, they have suggested that 
patients with CDGP reach their PAH and TH even without 
medical treatment. The study sample (11 boys) and the 
average patients’ final height (165.7 cm) were less than 
those in previous studies; however, the socio-economic 
state of the study group was unknown and patients’ TH 
and FH were both at the lower limit of normal. In this 
study, the statistical significance or lack of significance 
between FH, TH and PAH has not been detailed. Curtis 
et al. (17) believe that boys with CDGP will finally reach 
their normal adult height of slightly less than predicted 
height calculated by parental height.
Table 1 Baseline demographic characteristic of patients.
Characteristics Mean ± s.d. Range
Age (years) 15.2 ± 0.95 14–16.5
Height (cm) 150.16 ± 7.1 138.5–160
Height SDS −2.9 ± 0.77
BMI (kg/m2) 18.5 ± 0.37 14.80–30
Bone age (years) 12.97 ± 1 10–14.5
Bone age delay (years) 2.2 ± 0.82 1–3.5
Table 2 Mean ± s.d. of final or near final height, target 
height and predicted adult height.
Characteristics Mean ± s.d. Range
Final or near final height (cm) 165.7 ± 2.89
SDS of final or near final height −1.95 ± 0.44
Target height 171.8 ± 4.65 162–179
SDS of target height (cm) –0.87 ± 0.77
Predicted adult height 170.7 ± 5.17 161.3–177
SDS of predicted adult height –1.05 ± 0.95
Final bone age 17.16 ± 0.58 16.5–18
Table 3 Correlation between final or near final height and 
all other parameters.
Parameters R P value
BMI 0.145 >0.05
Target height 0.2 <0.0001
Predicted adult height 0.32 <0.0001
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Conclusion
According to the results of this study and similar studies, 
most patients with CDGP do not reach their target height 
or predicted adult height; they are usually shorter than 
their parents and general population. Such patients need 
to be followed up until they reach their FH and in some 
cases, adjunctive medical treatment might be indicated.
Limitation of the study
The limitation of current study was small sample size 
because only 15 patients had inclusion criteria.
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